Metabolism and Disposition of the HIV-1 Protease Inhibitor Lopinavir (ABT-378) Given in Combination with Ritonavir in Rats, Dogs, and Humans

@article{Kumar2004MetabolismAD,
  title={Metabolism and Disposition of the HIV-1 Protease Inhibitor Lopinavir (ABT-378) Given in Combination with Ritonavir in Rats, Dogs, and Humans},
  author={G. Nirmal Kumar and Venkata K. Jayanti and Marianne Johnson and John T Uchic and Samuel Thomas and R. van der Lee and Brian A. Grabowski and Hing Leung Sham and Dale J. Kempf and Jon F. Denissen and Kennan C. Marsh and Eugene F Sun and Stanley A. Roberts},
  journal={Pharmaceutical Research},
  year={2004},
  volume={21},
  pages={1622-1630}
}
Purpose. The objective of this study was to examine the metabolism and disposition of the HIV protease inhibitor lopinavir in humans and animal models. Methods. The plasma protein binding of [14C]lopinavir was examined in vitro via equilibrium dialysis technique. The tissue distribution of radioactivity was examined in rats dosed with [14C]lopinavir in combination with ritonavir. The metabolism and disposition of [14C]lopinavir was examined in rats, dogs, and humans given alone (in rats only… CONTINUE READING